PLK1 and cancer: Analysis of drug sensitivities between SCLC-Y and other subtypes of SCLC cell lines using the Cancer Therapeutics Response Portal database revealed specific drug candidates, including PLK1 inhibitors, that showed potent and highly selective activity in SCLC-Y cell lines (Figure 4d; Supplemental Table S2).